MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market [Yahoo! Finance]
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) [Yahoo! Finance]
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings [Yahoo! Finance]